May 26, 2009 - Encouraging Data from Independent Clinical Study Assessing the Effects of Oral GLP-1 and PYY3-36, Combined with Eligen(R) Technology on Appetite Suppression- Emisphere Technologies, Inc. (NASDAQ: EMIS) announced data from a clinical study designed to assess the effect of oral administration of two peptides, GLP-1 and PYY3-36, utilizing Emisphere's Eligen(R) Technology on appetite suppression. The study was conducted at the University Hospital in Basel, Switzerland by Professor Christoph Beglinger, of the Clinical Research Center, Department of Biomedicine Division of Gastroenterology, andDepartment of Clinical Pharmacology and Toxicology at the hospital.The randomized, double-blind, placebo-controlled trial was conducted in 16 normal weight males between the ages of 18 and 40. The study was designed to investigate the effects of orally administered GLP-1 and PYY3-36 formulated with Emisphere's Sodium N-[8-(2-hydroxybenzoyl) Amino] Caprylate ("SNAC") carrier and their potential effect in the control of food intake and satiety. Prior studies have shown the ability of both peptides to reduce appetite and food consumption in healthy subjects and in patients with obesity... Emisphere Technologies' Press Release -
